Shire PLC (NASDAQ:SHPG)‘s stock had its “buy” rating reiterated by stock analysts at Jefferies Group in a research report issued to clients and investors on Tuesday. They currently have a $262.00 price objective on the biopharmaceutical company’s stock. Jefferies Group’s target price suggests a potential upside of 28.43% from the stock’s previous close.

SHPG has been the topic of a number of other research reports. Shore Capital restated a “buy” rating on shares of Shire PLC in a research report on Tuesday, August 30th. Zacks Investment Research upgraded Shire PLC from a “hold” rating to a “buy” rating and set a $208.00 price objective on the stock in a report on Tuesday, July 5th. Citigroup Inc. reiterated a “buy” rating on shares of Shire PLC in a report on Monday. Leerink Swann reiterated a “buy” rating and issued a $213.00 price objective (down previously from $225.00) on shares of Shire PLC in a report on Thursday, June 16th. Finally, Goldman Sachs Group Inc. reiterated a “buy” rating on shares of Shire PLC in a report on Tuesday, June 28th. Four equities research analysts have rated the stock with a hold rating and twenty-three have issued a buy rating to the stock. Shire PLC currently has an average rating of “Buy” and a consensus price target of $230.67.

Shares of Shire PLC (NASDAQ:SHPG) opened at 204.00 on Tuesday. Shire PLC has a 1-year low of $147.60 and a 1-year high of $231.32. The firm has a 50-day moving average price of $196.07 and a 200-day moving average price of $183.99. The stock has a market capitalization of $60.76 billion, a PE ratio of 42.39 and a beta of 1.11.

Shire PLC (NASDAQ:SHPG) last posted its earnings results on Tuesday, August 2nd. The biopharmaceutical company reported $3.38 EPS for the quarter, beating the Zacks’ consensus estimate of $3.03 by $0.35. Shire PLC had a return on equity of 17.70% and a net margin of 13.19%. The company had revenue of $2.43 million for the quarter, compared to the consensus estimate of $2.28 billion. During the same quarter in the previous year, the business earned $2.63 earnings per share. The company’s revenue for the quarter was up 55.9% on a year-over-year basis. On average, equities research analysts forecast that Shire PLC will post $12.93 earnings per share for the current year.

The business also recently disclosed a dividend, which will be paid on Friday, October 7th. Shareholders of record on Friday, September 9th will be paid a dividend of $0.139 per share. The ex-dividend date of this dividend is Wednesday, September 7th. Shire PLC’s dividend payout ratio is presently 15.63%.

A number of hedge funds have recently bought and sold shares of the stock. Macquarie Group Ltd. bought a new stake in Shire PLC during the second quarter valued at approximately $5,561,000. Northwestern Mutual Wealth Management Co. increased its stake in Shire PLC by 157.9% in the second quarter. Northwestern Mutual Wealth Management Co. now owns 8,645 shares of the biopharmaceutical company’s stock valued at $1,591,000 after buying an additional 5,293 shares in the last quarter. Cowen Group Inc. bought a new stake in Shire PLC during the second quarter valued at approximately $920,000. Beacon Trust Co. bought a new stake in Shire PLC during the second quarter valued at approximately $2,643,000. Finally, IFP Advisors Inc increased its stake in Shire PLC by 871.9% in the second quarter. IFP Advisors Inc now owns 2,702 shares of the biopharmaceutical company’s stock valued at $497,000 after buying an additional 2,424 shares in the last quarter. 24.26% of the stock is owned by hedge funds and other institutional investors.

Shire PLC Company Profile

Shire plc is a biotech company. The Company, along with its subsidiaries, is engaged in developing and marketing medicines for patients with rare diseases and other select conditions. The Company operates in the segment of research, development, licensing, manufacturing, marketing, distribution and sale of specialist medicines.

5 Day Chart for NASDAQ:SHPG

Receive News & Ratings for Shire PLC Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Shire PLC and related companies with MarketBeat.com's FREE daily email newsletter.